Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of SCH 527123 in Subjects With Neutrophilic Asthma.

Trial Profile

Safety of SCH 527123 in Subjects With Neutrophilic Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Navarixin (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 01 Jul 2012 Results published in Clinical and Experimental Allergy.
    • 28 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
    • 19 May 2010 Results will be presented at the 106th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top